A CITF-funded study, led by Drs. Brian Grunau and David Goldfarb and Pascal Lavoie (University of British Columbia), and Sheila O’Brien and Steven Drews of Canadian Blood Services, and published in Open Forum Infectious Diseases, tested the sensitivity of the Roche anti-SARS-CoV-2 nucleocapsid assay.